Okamura Takehiko, Akita Hidetoshi, Ando Ryosuke, Kawai Yasunori, Tozawa Keiichi, Kohri Kenjiro
Department of Urology, J.A. Aichi Anjo Kosei Hospital, Anjo, Japan.
Asian Pac J Cancer Prev. 2010;11(4):1107-10.
With T1G3 bladder cancer, it remains unresolved whether the best treatment option is bladder preservation or total cystectomy. To assess the feasibility of the first option, we performed a clinical evaluation of the efficacy of intravesical instillation of bacillus Calmette-Guerin (BCG) for prevention of T1G3 bladder cancer recurrence after transurethral resection of bladder tumor (TUR-Bt).
A total of 30 patients with T1G3 bladder cancers received 6 to 8 weekly instillations of BCG followed in some cases by further applications at monthly intervals.
Recurrence occurred in 13 cases. There were 6 patients with progression, total cystectomy being performed for 5 of these. Further BCG-including treatments were performed in 7 patients, and all of them were alive at the end of the follow-up period. Finally, bladder preservation proved successful in 24 of 30 cases.
Intravesical instillation of BCG in high-risk T1G3 cases, including additional BCG treatment, proved effective and satisfactory in our series. Therefore, this option warrants emphasis with regard to its relative merit compared to total cystectomy.
对于T1G3期膀胱癌,最佳治疗方案是保留膀胱还是全膀胱切除术仍未明确。为评估第一种方案的可行性,我们对经尿道膀胱肿瘤电切术(TUR-Bt)后膀胱内灌注卡介苗(BCG)预防T1G3期膀胱癌复发的疗效进行了临床评估。
30例T1G3期膀胱癌患者接受了每周1次,共6至8次的卡介苗灌注,部分患者随后每月进行进一步灌注。
13例出现复发。6例病情进展,其中5例行全膀胱切除术。7例患者接受了包括卡介苗在内的进一步治疗,随访期末所有患者均存活。最终,30例中有24例成功保留膀胱。
在我们的系列研究中,高危T1G3期病例膀胱内灌注卡介苗,包括额外的卡介苗治疗,证明是有效且令人满意的。因此,与全膀胱切除术相比,该方案的相对优点值得强调。